Here’s what you should know.
1. Takeda’s Chief Executive Christophe Weber said in a results briefing that “Takeda has for many years been reasonable in its price increases in the United States and we are very committed to single-digit price increase [model].”
2. The United States is Takeda’s biggest market outside of Japan, accounting for a third of its drug revenues.
3. President Trump would like pharmaceutical companies to lower prices and produce more drugs in the United States.
4. Takeda is actively pursuing acquisitions to “bolster its drug portfolio and expand to more overseas markets.”
More articles on gastroenterology/endoscopy:
Gastro Health, LLC announces the acquisition of Douglas M. Weissman, M.D., P.A., one of the leading gastroenterology practices in Coral Springs, FL.
GI leader to know: Dr. Gregg Polidori of Oakland Gastroenterology
Residents, program directors encouraged to prepare for new education endoscopy requirement: 4 takeaways
